Low Toxicity Reported With AIDS Drug CS-85

Helquist, Michael
January 1987
Advocate;1/6/87, Issue 463, p23
Reports that the drug AZT continues to be a focal point for the hopes of people infected with HIV and those diagnosed with AIDS. Emphasis made on the lower mortality rate associated with the drug; Inhibition of the growth of the HIV.


Related Articles

  • The AZT fire storm. Gallagher, John // Advocate;5/18/93, Issue 629, p29 

    Reports on the controversy surrounding the effectiveness of AZT in the treatment of AIDS. Article published in a medical journal claiming that the antiviral drug may not slow the onset of AIDS in HIV-infected persons; Reaction of AIDS activists.

  • AZT is shit. Kramer, Larry // Advocate;5/18/93, Issue 629, p80 

    Focuses on the ineffectiveness of AZT in the treatment of AIDS. Criticism on concerned agencies for failure to discover and produce AIDS drugs; Government budget for AIDS research.

  • Timing of AZT. M.O.R. // Cortlandt Forum;03/25/97, Vol. 10 Issue 3, p139 

    Warns against the use of zidovudine monotherapy in newly diagnosed HIV patients. Drugs which could be combined with zidovudine to increase anti-HIV activity; Factors on which decisions about when to initiate treatment are usually based.

  • AZT Summary. Helquist, Michael // Advocate;4/28/87, Issue 471, p23 

    Discusses issues related to AZT, the first AIDS drug licensed by the U.S. Food and Drug Administration. Marketing of the drug under the brand name Retrovir; Limited supplies of the drug; Recommended dosage.

  • No Time to Relax. Helquist, Michael // Advocate;4/28/87, Issue 471, p23 

    Focuses on licenses for the AIDS drug AZT or Retrovir in the U.S., Great Britain and France. Hope given to people infected with HIV; Criticism on the limited availability of the drug; Flaws in the American health care system and the government's response to AIDS research.

  • Optimism about New Drug. Helquist, Michael // Advocate;3/4/86, Issue 441, p23 

    Highlights the results of a small-scale clinical trial of azidothymidine. Efficacy of the drug in preventing the AIDS virus from reproducing in the body; Need for more extensive studies.

  • Yet People Aren't Rushing To Begin AZT. Helquist, Michael // Advocate;4/10/90, Issue 548, p24 

    Reports on a survey of 47 AIDS service organizations in the U.S. conducted by the National AIDS Network, which found that many of the projects were unprepared to meet the anticipated demand for information and testing services following the government's approval of AZT treatment for AIDS....

  • ACYCLOVIR REVIEWED.  // Advocate;9/20/94, Issue 664, p25 

    Reports on the data from the Multicenter AIDS Cohort Study which reveals that people with AIDS who received both AZT and acyclovir showed significant decrease in the probability of death compared to those who did not take acyclovir.

  • Zidovudien for Early Human Immunodeficiency Virus (HIV) Infection: Who, When, and How? Ruedy, John; Schechter, Martin; Montaner, Julio S. G. // Annals of Internal Medicine;5/15/90, Vol. 112 Issue 10, p721 

    Editorial. Discusses the use of zidovudine to alter the rapid fatal course of AIDS. Details of an initial placebo-controlled trial which provided evidence for the effectivity of the drug; Basis for the decision to start zidovudine therapy in a given individual; Hematologic effect of the drug.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics